Trials / Terminated
TerminatedNCT03138538
M8891 First in Human in Solid Tumors
An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- EMD Serono Research & Development Institute, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic (PK), pharmacodynamic and clinical activity of M8891 as single agent in participants with advanced solid tumors in Part 1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Part 1: M8891 | Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. |
Timeline
- Start date
- 2017-08-08
- Primary completion
- 2020-09-16
- Completion
- 2020-09-16
- First posted
- 2017-05-03
- Last updated
- 2022-03-11
- Results posted
- 2022-03-11
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03138538. Inclusion in this directory is not an endorsement.